Septerna has developed a native complex platform that can reconstitute the GLP-1 receptor within an artificial lipid bilayer, complexed with combinations of drug and internal cell signalling molecules, which replicates the dynamics of the signalling process at scale
Public health systems in these regions are also recognizing obesity as a major contributor to non-communicable diseases such as type 2 diabetes, cardiovascular disease, and fatty liver disease
In short, the regulatory lesson is one of control and transparency : integrating AI does not diminish the sponsors liability
Blood Sugar Fluctuations GLP-1 drugs help stabilize blood sugar, but during the early stages, some patients might experience mild hypoglycemia or fluctuations
Typically 2 to 4kg in the first month on starting dose
Wegovy activates one (GLP-1)